Definium Therapeutics’ (DFTX) “Overweight” Rating Reiterated at Piper Sandler

Posted by George Bondi on Aug 7th, 2026

Definium Therapeutics (NASDAQ:DFTX – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Piper Sandler in a report released on Friday,Benzinga reports. They presently have a $75.00 price target on the stock, up from their prior price target of $73.00. Piper Sandler’s target price points to a potential upside of 65.86% from the stock’s previous close.

DFTX has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. JonesTrading raised their target price on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Oppenheimer set a $60.00 price objective on Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $55.00.

Check Out Our Latest Stock Analysis on DFTX

Definium Therapeutics Stock Performance

Shares of DFTX traded down $0.92 on Friday, reaching $45.22. The company’s stock had a trading volume of 1,534,675 shares, compared to its average volume of 2,250,882. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The stock has a market capitalization of $4.51 billion, a P/E ratio of -18.16 and a beta of 2.23. The stock’s 50 day simple moving average is $37.45 and its two-hundred day simple moving average is $25.72. Definium Therapeutics has a 12-month low of $8.70 and a 12-month high of $49.70.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Research analysts forecast that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This trade represents a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several large investors have recently made changes to their positions in DFTX. Bank of New York Mellon Corp boosted its stake in shares of Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after acquiring an additional 24,349 shares during the period. Flagship Harbor Advisors LLC bought a new stake in Definium Therapeutics during the 4th quarter valued at approximately $117,000. Caxton Associates LLP purchased a new position in Definium Therapeutics in the 3rd quarter worth approximately $126,000. Sender Co & Partners Inc. bought a new position in Definium Therapeutics in the 3rd quarter worth approximately $305,000. Finally, Scientech Research LLC bought a new position in Definium Therapeutics in the 3rd quarter worth approximately $286,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.